JP2024527235A5 - - Google Patents
Info
- Publication number
- JP2024527235A5 JP2024527235A5 JP2023574356A JP2023574356A JP2024527235A5 JP 2024527235 A5 JP2024527235 A5 JP 2024527235A5 JP 2023574356 A JP2023574356 A JP 2023574356A JP 2023574356 A JP2023574356 A JP 2023574356A JP 2024527235 A5 JP2024527235 A5 JP 2024527235A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213478P | 2021-06-22 | 2021-06-22 | |
| US63/213,478 | 2021-06-22 | ||
| US202163242929P | 2021-09-10 | 2021-09-10 | |
| US63/242,929 | 2021-09-10 | ||
| PCT/US2022/034373 WO2022271722A1 (en) | 2021-06-22 | 2022-06-21 | Anti-egfrviii antibody drug conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527235A JP2024527235A (ja) | 2024-07-24 |
| JP2024527235A5 true JP2024527235A5 (https=) | 2025-06-25 |
Family
ID=82655068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574356A Pending JP2024527235A (ja) | 2021-06-22 | 2022-06-21 | 抗ＥＧＦＲｖＩＩＩ抗体薬物コンジュゲート及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240293566A1 (https=) |
| EP (1) | EP4359440A1 (https=) |
| JP (1) | JP2024527235A (https=) |
| KR (1) | KR20240024061A (https=) |
| AU (1) | AU2022298653A1 (https=) |
| CA (1) | CA3212850A1 (https=) |
| IL (1) | IL309048A (https=) |
| MX (1) | MX2023014683A (https=) |
| WO (1) | WO2022271722A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| AU2002311919B8 (en) | 2001-05-11 | 2007-03-22 | Ludwig Institute For Cancer Research Ltd | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| KR20130065723A (ko) | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US8409838B2 (en) | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JP6632984B2 (ja) * | 2014-03-11 | 2020-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ＥＧＦＲｖＩＩＩ抗体およびその使用 |
| AU2017277534A1 (en) * | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
| RU2018147224A (ru) * | 2016-06-08 | 2020-07-14 | Эббви Инк. | Конъюгаты антитела к egfr и лекарственного средства |
-
2022
- 2022-06-21 JP JP2023574356A patent/JP2024527235A/ja active Pending
- 2022-06-21 US US18/572,930 patent/US20240293566A1/en active Pending
- 2022-06-21 WO PCT/US2022/034373 patent/WO2022271722A1/en not_active Ceased
- 2022-06-21 CA CA3212850A patent/CA3212850A1/en active Pending
- 2022-06-21 MX MX2023014683A patent/MX2023014683A/es unknown
- 2022-06-21 EP EP22744564.0A patent/EP4359440A1/en active Pending
- 2022-06-21 IL IL309048A patent/IL309048A/en unknown
- 2022-06-21 KR KR1020237041451A patent/KR20240024061A/ko active Pending
- 2022-06-21 AU AU2022298653A patent/AU2022298653A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2694111T3 (en) | Antibody pharmaceutical conjugates | |
| JP2022510964A5 (https=) | ||
| JP2017510559A5 (https=) | ||
| JP2019107018A5 (https=) | ||
| RU2013108054A (ru) | Антитела против а2 тенасцина с и способы их применения | |
| JP2023515941A5 (https=) | ||
| JP2024544520A5 (https=) | ||
| CN113509558B (zh) | 四价抗体药物偶联物及其应用 | |
| KR20230018454A (ko) | 항-c-Met 항체-약물 접합체 및 이의 용도 | |
| JP2025513721A5 (https=) | ||
| WO2016116399A1 (en) | Anti-fibroblast activation protein (fap) antibodies for treatment and diagnosis | |
| JP2024527235A5 (https=) | ||
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| JP2025511135A5 (https=) | ||
| JP2023502398A5 (https=) | ||
| WO2022228424A1 (zh) | 一种抗egfr/vegf双功能融合蛋白及其用途 | |
| JP2023546293A5 (https=) | ||
| EP4417622A1 (en) | Anti-cd26 antibody and use thereof | |
| RU2023130344A (ru) | КОНЪЮГАТЫ АНТИТЕЛА К EGFRvIII И ЛЕКАРСТВЕННОГО СРЕДСТВА И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| WO2023045859A1 (zh) | Cd38单克隆抗体及其应用 | |
| CN119156399A (zh) | 抗人颗粒蛋白前体的全人源单克隆抗体 | |
| CN119744272A (zh) | 一种抗ror1蛋白的抗体及其缀合物 | |
| JP2024546130A5 (https=) | ||
| WO2026052074A1 (zh) | 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用 | |
| RU2024137222A (ru) | Антитело к CLDN18.2 и его фармацевтическая композиция и применение |